Capital Advisors Inc. OK Reduces Stock Position in Novo Nordisk A/S (NYSE:NVO)

Capital Advisors Inc. OK lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 24.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 66,892 shares of the company's stock after selling 21,554 shares during the period. Capital Advisors Inc. OK's holdings in Novo Nordisk A/S were worth $7,965,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GQG Partners LLC boosted its position in Novo Nordisk A/S by 654.6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company's stock worth $466,485,000 after acquiring an additional 3,151,584 shares during the last quarter. International Assets Investment Management LLC increased its position in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the period. Acadian Asset Management LLC grew its stake in shares of Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company's stock valued at $159,703,000 after buying an additional 1,155,313 shares during the period. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.0 %

Shares of NYSE NVO traded down $0.01 on Friday, hitting $111.94. The company had a trading volume of 4,554,729 shares, compared to its average volume of 4,701,665. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The firm has a market capitalization of $502.33 billion, a P/E ratio of 38.34, a PEG ratio of 1.46 and a beta of 0.43. The business has a 50 day moving average of $124.25 and a two-hundred day moving average of $130.90.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts' consensus estimates of $0.71 by ($0.06). The company had revenue of $9.82 billion during the quarter, compared to analysts' expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S's dividend payout ratio (DPR) is 24.66%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on NVO shares. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.